Introduction. Borderline ovarian tumors are typically indolent neoplasms. Since many are diagnosed in younger women, fertility conservation is an important consideration and has been advocated based on retrospective data. The objective of this study was to identify features impacting on recurrence and survival in a series of borderline ovarian tumors, and to assess the safety of a fertility-sparing approach. Material and methods. A historical cohort study of consecutive borderline ovarian tumors cases treated at a single institution over 30 years . Data on surgical approach (fertility-sparing or otherwise), disease stage, CA125 levels, histological features, adjuvant treatment and follow-up data were collected. Recurrence and survival were assessed using the Kaplan-Meier method and associations with the variables of interest were evaluated using a multivariate Cox proportional hazards model. Results. 213 patients were included. Of 132 women age 40 years and below at diagnosis, 112 (85%) had a fertility-sparing procedure and 60 (46%) had conservation of an involved ovary. Fifty patients (24%) developed recurrences; fertility preservation (hazard ratio = 2.57; 95% confidence interval 1.1-6; p = 0.029) and advanced stage (hazard ratio = 4.15; 95% confidence interval 2.3-7.6; p < 0.001) were independently associated with recurrence on multivariate analysis. Eleven (5%) patients died of their disease. Fertility preservation was not associated with compromised survival. Conclusions. Borderline ovarian tumors carry a good prognosis overall. Fertility preservation is associated with a higher risk of disease relapse; however, as most relapses are localized and may be salvaged with surgical treatment, overall survival is not compromised.
Introduction
Borderline ovarian tumors (BOT) account for about 10-20% of all epithelial ovarian tumors (1, 2) and are typically indolent neoplasms (2) (3) (4) (5) . Most patients present with localized disease, and even patients with advanced stage at presentation may expect extended survival (4) (5) (6) (7) . Disease extent at diagnosis as well as histological subtype and other histologic features, Mean age at diagnosis is significantly younger for BOT than for invasive epithelial ovarian cancer and is reported to be 40-55 years across studies (1, 5, 10, 11) . Since BOT are often diagnosed in women who have not completed childbearing, fertility is an important consideration in planning treatment.
The objectives of this study were to assess the impact of fertility-preserving surgery on disease outcomes such as recurrence and survival in a cohort of patients with BOT, and to investigate the effects of previously described prognostic features on disease outcomes in this patient population.
Material and methods
Consecutive women with BOT treated at the Chaim Sheba Medical Center between the years 1981 and 2011 were identified from a prospectively maintained departmental database. Patients with insufficient data on histology or surgical extent, or those coming in for single consultations who did not continue follow up at Sheba were excluded.
Medical records, surgical report, pathology reports and chemotherapy records were reviewed. Data extracted included clinical and demographic variables, surgical information, histopathology details, use of chemotherapy and follow-up data comprising details of disease recurrence, treatment of recurrence(s) and survival.
The extent of surgery was determined by combining primary and completion surgery. Completion surgery may have been performed if patients were referred to the study center after an initial procedure elsewhere that established their diagnosis. Fertility preservation was defined as surgery sparing the uterus and some ovarian tissue to allow spontaneous conception in the future. Conservation of an involved ovary was defined as the removal of macroscopic tumor from an ovary while leaving apparently healthy ovarian tissue intact.
The FIGO 2009 staging system for epithelial ovarian tumors was used for determining disease stage. Early disease was defined as FIGO stages IA-IB, and advanced disease as FIGO stages IC and above. Histological information included tumor type (serous, mucinous or endometrioid), features such as a micropapillary pattern and intraepithelial carcinoma, and implant type (invasive vs. non-invasive) in patients with peritoneal disease. Pathology was reported by experienced pathologists in a tertiary academic cancer center.
Borderline ovarian tumors was diagnosed when proliferation of the epithelial cells lining the ovarian cysts was observed, with the formation of papillary projections in more than 10% of the lining epithelium, mild to moderate nuclear atypia, minimal mitotic activity and the absence of destructive stromal invasion. A micropapillary pattern was reported when non-hierarchical branching architecture of papillae five times taller than they are wide was present in a serous borderline tumor. Intraepithelial carcinoma was diagnosed when a borderline tumor showed severe nuclear atypia but no stromal invasion was identified. Microinvasion was diagnosed when a focus of stromal invasion was limited to an area of no more than 10 mm 2 .
Statistical analyses
A comparative analysis was performed between patients who had fertility-sparing surgery and those who did not, including demographic, pathologic and clinical features. Recurrence-free and overall survival were assessed using the Kaplan-Meier method and the log-rank test. The associations of clinical, pathological and surgical variables with recurrence and overall survival were assessed using the Cox proportional hazards method; multivariate analysis was used to identify independent associations. The study cohort was powered to detect a 15% difference in recurrence and survival with a power of 80% and a confidence level of 95%. All statistical analyses were performed on SPSS software version 23 (IBM analytics, Armonk, NY, USA).
Ethical approval
Data collection and analysis were approved by the Chaim Sheba Medical Center institutional review board (SMC-1127-14 dated 6 April 2014).
Results
In all, 234 women with BOT were identified. The patient cohort consisted of 213 who had sufficiently complete data on record. Mean follow up for the study population was 75 months, with a total follow-up period of 1331 person-years.
Disease characteristics
Staging included peritoneal biopsies and an omentectomy in all cases; lymphadenectomy was performed as part of the staging procedure in the earlier study period and was reported in 102 of patients. In all, 167 women (81%) were diagnosed with stage I disease, eight women (4%) had stage II disease at diagnosis and 31 (15%) had stage III disease. Mean CA125 value was 195 at diagnosis and correlated with disease stage. Of 41 patients with peritoneal spread, 11 had invasive peritoneal implants. Fifteen patients received chemotherapy after surgery for advanced disease, primarily in the earlier years of the study.
Histology was most commonly serous: 140 patients had serous BOT, 69 had mucinous tumors and four had endometrioid neoplasms. Of the 140 serous tumors, 28 had a micropapillary pattern. Of the mucinous tumors, 18 had intraepithelial carcinoma and 21 had an area of microinvasion.
Fertility preservation
The mean age in the entire study population was 38.7 years (SD 14.9). In all, 132 (62%) of women included were 40 years and younger. Among these, 112 (85%) had fertility-preserving surgery; in 60 (45%) women, an ovary with macroscopic disease was conserved after removing the tumor. A comparison of patients who had fertility-sparing surgery and those whose fertility was compromised is presented in Table 1 .
Sixty-seven (67) pregnancies were documented in 42 of 112 women (38%) who had fertility-preserving surgery, and more than one pregnancy was documented in 22 women.
Disease outcome
Fifty patients (24%) developed recurrences; 40 of these had had fertility-sparing surgery and 10 had had radical surgery. Relapse was localized in 37 patients and disseminated (usually peritoneal) in 11 cases. The 48 patients with a recurrence were treated surgically; eight of these recurrences were invasive. Twenty patients had more than one recurrence, and 12 of them were treated surgically more than once. All further surgery on women who initially had a fertility-sparing procedure was done for disease recurrence or other pathologies; no prophylactic surgery at the end of childbearing was undertaken.
Univariate analysis found an association between recurrence and a number of factors, including disease stage and peritoneal spread, CA125 levels, serous histology, fertility preservation and ovarian conservation. Age was also included in the multivariate analysis because of its covariance with the performance of fertility-preserving surgery. On multivariate regression analysis, only fertility preservation [hazard ratio (HR) = 2.57; 95% CI 1.1-6; p = 0.029) and advanced stage (HR = 4.15; 95% CI 2.3-7.6; p < 0.001) were found to be independently associated with recurrence (Table 2) .
Twenty patients (9%) died over the course of followup. Only 11 succumbed to their disease; nine women died with no documented recurrence. Six of these 11 cases (55%) had fertility-preserving surgery; eight (73%) had stage 1C or higher disease at diagnosis. Most (8/11, 73%) had more than one recurrence before succumbing to disease. Fertility preservation and ovarian conservation were not associated with overall survival on either logrank test or Cox regression analysis. Multivariable regression analysis of overall survival revealed an independent association only with chemotherapy, with patients receiving chemotherapy more likely to die (HR = 15.2, p < 0.001). Disease stage, histology, invasive peritoneal implants, cyst rupture, the performance of a lymphadenectomy, and fertility-sparing surgery had no independent association with survival. Kaplan-Meier curves for progression-free and overall survival are shown in Figures 1 and 2 .
Discussion
Borderline ovarian tumors are characterized by epithelial proliferation and atypia without stromal invasion. These tumors are significantly less prevalent than invasive epithelial ovarian cancers, with age-adjusted prevalence rates estimated at 1.5-3.0 per 100 000 (2, 12) . Because of the rarity of BOT, high quality data are lacking and our decisions on the management of these tumors rely heavily on retrospective series and population-based studies. Borderline ovarian tumors are diagnosed at significantly younger ages than invasive epithelial ovarian cancers; mean age at diagnosis has been reported as 45-50 years (2, 13) . This makes fertility an important consideration in planning treatment. In the current study population, mean age was 39 years and 62% were diagnosed at age 40 and younger; this is an exceptionally young BOT population and compares to 45% below the age of 45 in a California population registry (2) and 36% below the age of 40 in a published SEER report (5) .
The majority of BOT are diagnosed with early disease; the prevalence of advanced disease is reported to be as low as 8-15% (2,5,13). Many cases of early disease are diagnosed after a cystectomy has been performed for an apparently benign neoplasm, and further managementincluding the consideration of completion oophorectomy or any other fertility-compromising procedures -is only contemplated postoperatively. Even in cases where an intraoperative pathological examination establishes the diagnosis of BOT, the young age of the patients predisposes caregivers to consider conservative surgical management.
Data in the gynecological oncology literature has accumulated on the safety of fertility-preserving surgery for BOT across the disease spectrum (7, 14, 15) . Fertilitysparing surgery is commonly practiced in early disease (16) (17) (18) (19) (20) (21) (22) . Our group has previously published reports on conservative management of advanced BOT and found no impact on survival with fertility-preserving, and ovary-conserving, surgery (23) , as have other researchers (24) (25) (26) .
A comprehensive review of fertility-sparing surgery in BOT (15) concluded that the risk of relapse for conservatively managed early disease is 13%, whereas in advanced disease, this risk rises to 38%.
The present study includes 132 women 40 years and younger, 85% of whom had fertility-preserving surgery. This represents one of the larger series of conservatively managed BOT. In a recent systematic review of fertility preservation in BOT, of 40 studies included, only six reported on over 100 patients (15) . Fertility preservation was adopted more widely at our center than reported previously; in a large retrospective multicenter German report (13) , only 28% of patients under 55 years of age had fertility preservation. Multivariate Cox proportional hazards modeling found an increased risk for disease recurrence in patients who underwent fertility-preserving surgery, with an HR of 2.57. This association remained robust after adjusting for age, which was the main confounder. These findings are in line with reported outcomes from other groups (8, 9) .
In 45% of women 40 years and younger in this study population, a diseased ovary was conserved. This may have been a cystectomy or the cytoreduction of ovarian surface tumor. A number of reports advocate for the safety of cystectomy in the surgical management of BOT in early disease, including one of the few prospective trials on fertility preservation in BOT (16) (17) (18) (19) (20) (21) (22) . Although the likelihood of local recurrence in this situation may be Figure 1 . Disease-free survival for women undergoing fertilitypreserving surgery vs. women undergoing fertility-compromising surgery (Kaplan-Meier method). Fertility preservation is associated with shorter disease-free survival (mean, 177 months for patients having fertility-sparing surgery and 235 months for patients who did not, p < 0.001). higher (15, 18, 20) such recurrences are usually amenable to cure with repeat surgery; this may explain why the impact on patient survival is reported to be negligible (21, 23) . On the other hand, fertility outcomes are significantly improved when cystectomy rather than adnexectomy is performed (20) , which is a strong rationale for avoiding oophorectomy in patients who opt for fertility preservation. Although our data showed ovarian conservation to be associated with disease recurrence, no impact on overall survival was found, consistent with previous reports.
Conservative surgery for young patients with BOT is generally successful at preserving ovarian function, but conception rates among patients attempting pregnancy are variable: as high as 70-90% in Asian populations (10, 14, 27) but significantly lower, at 30-50%, in reports from Europe and Israel (7, 19, 20, 24, 28, 29) . This interesting discrepancy has been hypothesized to stem from a different distribution of tumor histology, with higher rates of mucinous tumors in Asian patient populations, resulting in a higher likelihood of unilateral, limited disease (15) . We report 67 pregnancies among 42 patients (38% of 112 patients who had fertility-preserving surgery); although this rate is in line with previous reports, it is probably an underestimation, as fertility data and the rate of attempted conception were poorly recorded.
Disease-related mortality for our patient population was under 5%, which was comparable to other reported data (13) . Mortality rates were similar in both surgical groups; in fact, no association was found between overall survival and fertility preservation, with multivariate analysis accounting for confounders such as age, disease stage and histology. The limited impact of fertility preservation on survival is again consistent with previous reports (7, 15, 28, (30) (31) (32) and is commonly attributed to the potential to cure recurrences with surgical treatment. However, like most studies on BOT, this analysis was underpowered to detect small overall survival differences.
Although not the focus of this study, it is interesting to note that adjuvant chemotherapy was associated with an increased risk of death. Lack of benefit from adjuvant chemotherapy is well documented (33) and the majority of prospective studies and restrospective series as well as a Cochrane review (34) do not support its use. The association found in our data is most likely explained by the selection of patients with high-risk disease to receive adjuvant treatment.
Strengths of this study include a large cohort of patients managed conservatively, and the comparability of the two surgical groups, including a similar stage distribution. Previous series looking at fertility-sparing surgery may have had trouble drawing definitive conclusions on survival because of imbalances between groups, such as more advanced disease among patients managed radically (15) .
Our study is limited by the inherent flaws of a retrospective design, as well as by a referral bias of patients undergoing treatment and follow up at a tertiary cancer center; however, a multicenter prospective study assessing the safety of fertility preservation in young patients with BOT is not likely to be feasible. Another limitation dictated by the rarity of these tumors is an extended study period, which exposes the study cohort to shifts in classification and in management. One example of this is a decline in complete surgical staging and in the use of chemotherapy for BOT over time; other issues include the emergence and evolution of the micropapillary subtype of serous BOT during the course of the study period.
Conclusion
A large proportion of patients with BOT are younger and have yet to complete their childbearing. These women may expect a favorable prognosis, with a low risk of mortality. Fertility-preserving surgery does increase the risk for relapse; this highlights the need for consistent and long-term follow up. Notably, fertility-sparing management does not appear to compromise overall survival, even in cases where both ovaries are involved in the disease process, or when disease has spread beyond the ovaries. As ever, practitioners should be cautioned that prospective long-term data are lacking, and that patients should be judiciously counseled before making an informed decision.
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